• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Century Therapeutics Inc. (Amendment)

    2/9/23 4:19:52 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IPSC alert in real time by email
    SC 13G/A 1 d442829dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO

    13d-2 (b)

    (Amendment No. 1)

     

     

    Century Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    15673T100

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      11,452,014 shares of Common Stock (2)

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      11,452,014 shares of Common Stock (2)

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,452,014 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      19.4% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Ventures VI GP, L.P. (“Versant VI GP LP”), Versant Ventures VI GP-GP, LLC (“Versant VI GP LLC”), Versant Vantage II, L.P. (“Vantage II”), Versant Vantage II GP, L.P. (“Vantage II GP LP”) and Versant Vantage II GP-GP, LLC (“Vantage II GP LLC” and together with Vantage II, Vantage II GP LP, Versant VI, Versant VI GP LP and Versant VI GP LLC, the “Reporting Persons”). Versant VI GP LP is the sole general partner of Versant VI and Versant VI GP LLC is the sole general partner of Versant VI GP LP, each of which may be deemed to have voting, investment and dispositive power over the securities held by Versant VI. Vantage II GP LP is the sole general partner of Vantage II and Vantage II GP LLC is the sole general partner of Vantage II GP LP, each of which may be deemed to have voting, investment and dispositive power over the securities held by Vantage II. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Versant VI. Versant VI GP LLC is the sole general partner of Versant VI GP LP, which is the sole general partner of Versant VI. Each of Versant VI GP LLC and Versant VI GP LP share voting, investment and dispositive power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed with the United States Securities and Exchange Commission (the “Commission”) on November 10, 2022 (the “Form 10-Q”).


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      11,452,014 shares of Common Stock (2)

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      11,452,014 shares of Common Stock (2)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,452,014 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      19.4% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Versant VI. Versant VI GP LLC is the sole general partner of Versant VI GP LP, which is the sole general partner of Versant VI. Each of Versant VI GP LLC and Versant VI GP LP share voting, investment, and dispositive power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Form 10-Q.


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      11,452,014 shares of Common Stock (2)

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      11,452,014 shares of Common Stock (2)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      11,452,014 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      19.4% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Versant VI. Versant VI GP LLC is the sole general partner of Versant VI GP LP, which is the sole general partner of Versant VI. Each of Versant VI GP LLC and Versant VI GP LP share voting, investment and dispositive power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Form 10-Q.


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      714,095 shares of Common Stock (2)

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      714,095 shares of Common Stock (2)

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      714,095 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      1.2% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Vantage II. Vantage II GP LLC is the sole general partner of Vantage II GP LP, which is the sole general partner of Vantage II. Each of Vantage II GP LLC and Vantage II GP LP share voting, investment and dispositive power over the securities held by Vantage II and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Form 10-Q.


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      714,095 shares of Common Stock (2)

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      714,095 shares of Common Stock (2)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      714,095 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      1.2% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Vantage II. Vantage II GP LLC is the sole general partner of Vantage II GP LP, which is the sole general partner of Vantage II. Each of Vantage II GP LLC and Vantage II GP LP share voting, investment and dispositive power over the securities held by Vantage II and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Form 10-Q.


    CUSIP No. 15673T100       13G            

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage II GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☒(1)

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      714,095 shares of Common Stock (2)

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      714,095 shares of Common Stock (2)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      714,095 shares of Common Stock (2)

    10.  

      Check if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      1.2% (3)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)

    These shares are held by Vantage II. Vantage II GP LLC is the sole general partner of Vantage II GP LP, which is the sole general partner of Vantage II. Each of Vantage II GP LLC and Vantage II GP LP share voting and investment power over the securities held by Vantage II and as a result may be deemed to have beneficial ownership over such securities.

    (3)

    This calculation is based upon 58,974,247 shares of the Issuer’s Common Stock outstanding as of November 4, 2022, as set forth in the Form 10-Q.


    Introductory Note: This Amendment No. 1 (the “Amendment”) amends and supplements the Schedule 13G originally filed by the Reporting Persons with the Commission on February 11, 2022 (the “Original Schedule 13G”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13G.

     

    Item 4

    Ownership.

    (a) Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person.*

    (b) Percent of class:

    See Row 11 of the cover page for each Reporting Person.*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person.*

    (ii) Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person.*

    (iii) Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person.*

    (iv) Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person.*

     

    *

    Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his, her or its pecuniary interest therein.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 9, 2023

     

    Versant Venture Capital VI, L.P.
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Versant Ventures VI GP, L.P.
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Versant Ventures VI GP-GP, LLC
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Versant Vantage II, L.P.
    By:   Versant Vantage II GP, L.P.
    Its:   General Partner
    By:   Versant Vantage II GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Versant Vantage II GP, L.P.
    By:   Versant Vantage II GP-GP, LLC
    Its:   General Partner
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Versant Vantage II GP-GP, LLC
    By:   /s/ Max Eisenberg
      Max Eisenberg, Chief Operating Officer
    Get the next $IPSC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IPSC

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00Buy
    Rodman & Renshaw
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    12/27/2022$19.00Buy
    Chardan Capital Markets
    10/31/2022$15.00Buy
    Guggenheim
    10/10/2022$28.00Buy
    Canaccord Genuity
    5/23/2022$27.00Buy
    H.C. Wainwright
    5/12/2022Mkt Perform
    William Blair
    11/19/2021$33.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $IPSC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cowan Chad bought $49,252 worth of shares (58,060 units at $0.85), increasing direct ownership by 6% to 1,045,087 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/29/25 4:52:27 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $30,352 worth of shares (52,000 units at $0.58), increasing direct ownership by 2% to 3,322,990 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/16/25 6:38:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $17,328 worth of shares (35,000 units at $0.50), increasing direct ownership by 1% to 3,271,453 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    11/20/25 6:02:42 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

    8/8/24 10:22:51 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics downgraded by JP Morgan with a new price target

    JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously

    8/28/23 7:15:43 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets initiated coverage on Century Therapeutics with a new price target

    Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00

    12/27/22 7:45:12 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    SEC Filings

    View All

    SEC Form S-3 filed by Century Therapeutics Inc.

    S-3 - Century Therapeutics, Inc. (0001850119) (Filer)

    2/5/26 4:06:10 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Century Therapeutics, Inc. (0001850119) (Filer)

    1/23/26 4:05:39 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Century Therapeutics Inc.

    SCHEDULE 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    1/16/26 4:34:53 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes

    PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The financing is being led by new investor TCGX, and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, an

    1/8/26 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

    PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees. "We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and

    12/9/25 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

    PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, NY, as follows: Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will participate in the "State of the Art in Cell Therapy" panel discussion at 12:00 p.m. ET on Tuesday, December 2, 2025.Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, and Dr. Cowan will participate in a webcasted fireside cha

    11/25/25 4:01:00 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP Finance & Operations Carr Douglas sold $589 worth of shares (323 units at $1.82), decreasing direct ownership by 0.06% to 514,551 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    2/5/26 4:14:34 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent was granted 475,000 shares, increasing direct ownership by 14% to 3,797,990 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    2/4/26 4:22:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Russotti Gregory was granted 135,000 shares, increasing direct ownership by 35% to 525,982 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    2/4/26 4:19:39 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Leadership Updates

    Live Leadership Updates

    View All

    Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

    PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees. "We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and

    12/9/25 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

    - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en

    3/14/24 7:30:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Financials

    Live finance-specific insights

    View All

    Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest

    5/9/24 7:30:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

    – Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – –   Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1

    12/9/23 12:00:00 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

    PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re

    12/6/23 7:30:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IPSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 5:46:35 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 4:08:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care